The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.

The Information in this section is intended for healthcare professionals only.

Please confirm that you are a healthcare professional.

Cookies

This site uses cookies for site interaction analysis with a purpose of service quality enhancing and uninterrupted site work. More details in Cookies Policy
Accept
01 February 2022

Darnitsa Produced 181 Million Packages of Medicines in 2021

01 February 2022

The Pharmaceutical Company Darnitsa remains the leader in the Ukrainian market as to sales of medicines in physical terms: last year the Company produced more than 181 million packages of medicines. According to Proxima Research, this allowed Darnytsia to cover 14.37% of the Ukrainian pharmaceutical market – twice as much as its nearest competitor. 

Darnitsa produces about 180 brands of medicines in 15 different forms: in the form of tablets, solutions, drops, powders, etc. In 2021, Darnitsa produced almost 19 million ampoules, about 9 million packs of infusion solutions and more than 134.5 million packs of tablets. Thus, the Company has maintained its leading position in the market for several years in a row: the every seventh package of medicines that is on pharmacy shelves, produced by Darnitsa*.

“Globally, our goal is for every Ukrainian to be able to buy the medicine he or she needs at any time. Darnitsa is constantly working on the introduction of innovative management and production technologies to provide the market with quality medicines in full. And our success in 2021 is the result of hard work aimed at the improvement of doctors’, health professionals’ and patients’ lives quality”, said Andrii Obrizan, Director General of the Pharmaceutical Company Darnitsa.

As have noted earlier in Darnitsa, efficient pharmaceutical production is a reliable foundation of national biosafety – full provision of Ukrainians with all necessary medicines and other medical devices. This was also emphasized by the Minister of Health of Ukraine Viktor Liashko during his visit to the Darnitsa production plant, where he saw with his own eyes an efficient, standardized European-style production process. According to Viktor Liashko, the Government considers support of the domestic pharmacy to be one of the main economic priorities.

“Coordinated cooperation with leaders of the pharmaceutical industry is the key to national security in the context of the COVID-19 pandemic and the successful response to other challenges to the country’s health care system. The state is interested in developing long-term and systematic cooperation with Ukrainian pharmaceutical companies. The development of national pharmaceutical production is one of the goals of the National Economic Strategy for the period up to 2030, which was approved by the Government in March 2021”, the Minister pointed out.

Reference

PJSC Pharmaceutical Company Darnitsa was founded in 1930. Since 1998, Darnitsa has been a Ukrainian leader in terms of production of medicines in kind. Strategic areas of portfolio development are cardiology, neurology, pain management. In the last five years, Darnitsa has brought to the market 63 new pharmaceutical brands.

* Proxima Research 2021 data

Share:
Specialized edition for medical institutions and doctors.